SCHEMBL2227633

SCHEMBL2227633

O=C(NCCN1CCCCC1)c1ccc2c(Cl)c3c(nc2c1)CCCC3

nearest known ligand 0.89

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.89
KMT2A Q03164 7/20 0.89
MEN1 O00255 6/20 0.89
ALDH1A1 P00352 2/20 0.89
SMN1; SMN2 Q16637 3/20 0.87
GAA P10253 1/20 0.87
GFER P55789 1/20 0.87
NPC1 O15118 2/20 0.67
RAB9A P51151 2/20 0.67
TP53 P04637 2/20 0.65
HTT P42858 2/20 0.65
THRB P10828 1/20 0.59
ATM Q13315 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
USP7 Q93009 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2229536 1.00 MAPT (0.89) MAPTKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL13822374 1.00 MAPT (0.89) MAPTKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL2219175 0.93 KMT2A (1.00) MAPTKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL2218106 0.87 KMT2A (0.88) MAPTKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL2217529 0.86 KMT2A (0.86) MAPTKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL2219588 0.86 KMT2A (1.00) MAPTKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL2228771 0.85 MAPT (0.77) MAPTKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL2227761 0.85 KMT2A (0.66) MAPTKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL14635011 0.83 LMNA (0.69) MAPTKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL2228666 0.82 KMT2A (0.68) MAPTKMT2AMEN1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2013-01-24 US claimed
US-9328093-B2 Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications HYBRIGENICS SA (FR) 2016-05-03 US disclosed
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2015-03-12 US disclosed
EP-2523938-B1 Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 HYBRIGENICS SA (FR) 2014-09-03 EP disclosed
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2013-01-24 US disclosed
EP-2523938-A1 AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 Hybrigenics S.A. (FR) 2012-11-21 EP disclosed
WO-2011086178-A1 AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 HYBRIGENICS SA (FR) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS USP7, SENP7, PSMA7 MAPT 704/4885KMT2A 2349/4885MEN1 4159/4885
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS USP7, SENP7, PSMA7 MAPT 704/4885KMT2A 2349/4885MEN1 4159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.